Intermediate-risk prostate cancer patients treated with androgen deprivation therapy and a hypofractionated radiation regimen with or without image guided radiotherapy

Radiation Oncology

Riccardo Maurizi Enrici¹  Vitaliana De Sanctis¹  Linda Agolli¹  Teresa Falco¹  Mattia Falchetto Osti¹  Stefano Bracci¹  Maurizio Valeriani¹ 

[1] Department of Radiation Oncology, La Sapienza University, Sant’Andrea Hospital, Via di Grottarossa 1035-1039, Rome, 00189, Italy

关键词: 3D-CRT;    IGRT;    Hypofractionated radiotherapy;    Intermediate-risk prostate cancer;   

Others  :  1153806
DOI  :  10.1186/1748-717X-8-137

 received in 2013-02-13, accepted in 2013-06-01,  发布年份 2013

【 摘 要 】

Background

To evaluate the efficacy of hypofractionated radiotherapy (HyRT) with or without image guided radiotherapy (IGRT) in intermediate risk prostate cancer.

Methods

105 patients were treated with HyRT, 43,8 Gy and 54,75 Gy were delivered to the seminal vescicles and to the prostate, respectively; 3,65 Gy/fraction three times weekly. All patients underwent 9 months hormonal therapy. Patient position was verified with daily kV cone beam CT in 69 patients (IGRT group). Acute and late toxicities were evaluated according to RTOG scale. Biochemical relapse was defined using PSA nadir + 2 ng/mL. The data were prospectively collected and retrospectively analyzed to evaluate the efficacy of IGRT.

Results

After a median follow-up of 31 months the actuarial 3-year bNED was 93,7%. During RT, 10.5% and 7.6% of patients developed ≥Grade 2 rectal and urinary toxicities, respectively. The cumulative incidence of ≥Grade 2 late rectal and urinary toxicities at 3 years were 6,9%, and 10,8%, respectively. The incidence of ≥Grade 2 late rectal toxicities was significant reduced in the IGRT group (1,6% vs. 14,5%, p=0,021). Two patients developed Grade 3 urethral obstruction and one patient developed grade 3 rectal bleeding.

Conclusions

HyRT represents a well-tolerated treatment able to achieve a high bNED. The use of daily IGRT is beneficial for reducing the incidence of late toxicities.

【 授权许可】

   
2013 Valeriani et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Viani GA, Stefano EJ, Afonso SL: Higher than conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized controlled trials. Int J Radiat Oncol Biol Phys 2009, 74:1405-1418.
• [2]Fowler JF: The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 2005, 44:265-276.
• [3]Fowler JF, Ritter MA, Chappell RJ, et al.: What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 2003, 56:1093-1104.
• [4]Lukka H, Hayter C, Julian JA, et al.: Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005, 23:6132-6138.
• [5]Yeoh EE, Botten RJ, Butters J, et al.: Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 2011, 81:1271-1278.
• [6]Michalski J, Winter K, Roach M, et al.: Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. Int J Radiat Oncol Biol Phys 2012, 83:e363-e370.
• [7]Arcangeli G, Saracino B, Gomellini S, et al.: A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010, 78:11-18.
• [8]Yassa M, Fortin B, Fortin MA, et al.: Combined hypofractionated radiation and hormone therapy for the treatment of intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2008, 71:58-63.
• [9]Faria S, Dal Pra A, Cury F, et al.: Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone. Radiother Oncol 2011, 101:486-489.
• [10]Dearnaley D, Syndikus I, Sumo G, et al.: Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary results from the CHHiP randomised controlled trial. Lancet Oncol 2012, 13:43-54.
• [11]Zilli T, Jorcano S, Rouzaud M, et al.: Twice-weekly hypofractionated intensity-modulated radiotherapy for localized prostate cancer with low-risk nodal involvement: toxicity and outcome from a dose escalation pilot study. Int J Radiat Oncol Biol Phys 2011, 81:382-389.
• [12]Martin JM, Rosewall T, Bayley A, et al.: Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2007, 69:1084-1089.
• [13]Kupelian PA, Willoughby TR, Reddy CA, et al.: Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007, 68:1424-1430.
• [14]Madsen BL, Hsi RA, Pham HT, et al.: Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007, 67:1099-1105.
• [15]Ju AW, Wang H, Oermann EK, et al.: Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer. Radiat Oncol 2013, 8:30. BioMed Central Full Text
• [16]Valeriani M, Monaco F, Osti MF, et al.: Hypofractionated radiotherapy with or without IGRT in prostate cancer: preliminary report of acute toxicity. Anticancer Res 2011, 31:3555-3558.
• [17]Mohler J, Bahnson RR, Boston B, et al.: NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Canc Netw 2010, 8:162e20.
• [18]Heemsbergen WD, Peeters STH, Koper PCM, et al.: Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. Int J Radiat Oncol Biol Phys 2006, 66:3-10.
• [19]Cox J, Stetz J, Pajak T: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for the Treatment and Research of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995, 31:1341-1346.
• [20]Waterhouse J, Metcalfe MC: Development of the sexual adjustment questionnaire. Oncol Nurs Forum 1986, 13:53-59.
• [21]Roach M 3rd, Hanks G, Thames H Jr, et al.: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
• [22]Wu J, Brasher P, El-Gayed A, et al.: Phase II study of hypofractionated image-guided radiotherapy for localized prostate cancer: outcomes of 55 Gy in 16 fractions at 3.4 Gy per fraction. Radiother Oncol 2012, 103:210-216.
• [23]Zelefsky MJ, Kollmeier M, Cox B, et al.: Improved clinical outcomes with high-dose image guided radiotherapy compared with Non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiation Oncol Biol Phys 2012, 84:125-129.
• [24]Dubray BM, Beckendorf V, Guerif S, et al.: Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediate analysis of GETUG 14 randomized trial (EU-20503/NCT00104741) [abstract]. Proc Am Soc Clin Oncol 2011, 29:s4521.
• [25]Zumsteg ZS, Spratt DE, Pei X, et al.: Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy. Int J Radiation Oncol Biol Phys 2012. in press
• [26]Zumsteg ZS, Zelefsky MJ: Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care? Lancet Oncol 2012, 13:e259-e269.